LEO Pharma to acquire gene therapy company Replay

Pharmaceutical Business Review

The acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector.

pharminent May 1, 2026 (Last updated: May 1, 2026)

Pharmaceutical Business Review

The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector.

Related Stories